Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion

Liver International

Volumn 30, Issue 10, 2010, Pages 1427-1438

  Chen, Pei Jer ^a   Furuse, Junji ^b   Han, Kwang Hyub ^c   Hsu, Chiun ^a   Lim, Ho Yeong ^d   Moon, HanLim ^e   Qin, Shukui ^f   Ye, Sheng Long ^g   Yeoh, Ee Min ^e   Yeo, Winnie ^h  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b KYORIN UNIVERSITY   (Japan)

^c Yonsei University College of Medicine   (South Korea)

^d Samsung Medical Center   (South Korea)

^e GLAXOSMITHKLINE   (Singapore)

^f No 81 Hospital of PLA   (China)

^g ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antineoplastic agents; Asia; Clinical practice patterns; Clinical trials; Hepatocellular carcinoma; Liver neoplasms

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; BEVACIZUMAB; BRIVANIB; CISPLATIN; DOXORUBICIN; ENTECAVIR; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; INTERFERON; LAMIVUDINE; LINIFANIB; MITOMYCIN C; PAZOPANIB; SORAFENIB; SUNITINIB; VANDETANIB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASIA; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CHEMOEMBOLIZATION; CHINESE MEDICINE; CLINICAL PROTOCOL; DISEASE SEVERITY; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HEPATITIS B VIRUS; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDICAL PRACTICE; MICROWAVE THERAPY; PATIENT SELECTION; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SIDE EFFECT; SKIN DISEASE; TRANSARTERIAL EMBOLIZATION AND CHEMOEMBOLIZATION; TREATMENT OUTCOME;

EID: 84984586721     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02292.x     Document Type: Review

References (64)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Yuen MF, Hou JL, Chutaputti A. Asia pacific working party on prevention of hepatocellular carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-53.
4. Llovet JM, Di Bisceglie AM, Bruix J, et al. Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
5. Bartlett DL, DiBisceglie AM, Dawson LA. Cancer of the liver. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 8th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2008; 1129-56.
6. Hsu C, Shen YC, Cheng CC, et al. Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials 2010; 31: 55-61.
7. Kim SR, Kudo M, Hino O, et al. For the organizing commmittee of the Japan-Korea liver symposium (JKLS). Epidemiology of hepatocellular carcinoma in Japan and Korea. Oncology 2008; 75: 13-6.
8. Han KH, Kim JK. Liver cancer in Korea. Hepatol Res 2007; 37: S106-9.
9. Luk JM, Wang X, Liu P, et al. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007; 27: 879-90.
10. Poon D, Anderson BO, Chen L-T, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian oncology summit 2009. Lancet Oncol 2009; 10: 1111-8.
11. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-33.
12. Chen C-H, Huanga G-T, Yanga P-M, et al. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 2006; 42: 2524-9.
13. Cantarini MC, Trevisani F, Morselli-Labate AM, et al. for the Italian liver cancer (ITA.LI.CA) group. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol 2006; 101: 91-8.
14. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-34.
15. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a metaanalysis. Liver Int 2008; 28: 28-38.
16. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28.
17. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-40.
18. Li N, Lai EC, Shi J, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2010; 17: 179-85.
19. Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1929-35.
20. Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med 2009; 48: 11-7.
21. Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96: 975-81.
22. Shen YC, Hsu C, Chen LT, et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010; 52: 889-94.
23. Weber S, Jarnagin W, Duffy A, et al. Liver and bile duct cancer. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff 's Clinical Oncology, 4th edn. Philadelphia, PA: Elsevier, 2008; 1569-84.
24. O'Neil BH, Venook AP. Hepatocellular carcinoma: the role of the north American GI steering committee hepatobiliary task force and the advent of effective drug therapy. Oncologist 2007; 12: 1425-32.
25. Ueno S, Tanabe G, Nuruki K, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 2002; 24: 395-403.
26. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: hepatobiliary cancers. v.2.2009. National Comprehensive Cancer Network Available at http://www.nccn.org (accessed 25 September 2009).
27. Kee KM, Wang JH, Lee CM, et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer 2007; 120: 2650-5.
28. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese university prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the liver Italian program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-9.
29. Chinese Society of Liver Cancer. The criteria of clinical diagnosis and staging of primary liver cancer. Chin J Hepatol 2001; 12: 324.
30. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502-10.
31. Yeo W, Liem TG, Chan SL, et al. Prognostic system for hepatitis B virus (HBV)-related hepatocellular carcinomaprospective validation of the Chinese university prognostic index. J Clin Oncol 2008; 26: abstract 4591.
32. Bruix J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
33. Japan Society of Hepatology. Clinical practice guidelines for hepatocellular cancer 2005. Available at http://www.jsh.or.jp/english/02-Contents.pdf (accessed 14 October 2009).
34. Korean Liver Cancer Study Group and National Cancer Center. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009; 15: 391-423.
35. Ng KK, Lo CM. Liver transplant in Asia: past, present and future. Ann Acad Med Singapore 2009; 38: 322-31.
36. Kudo M. Review of the 4th single topic conference on HCC. Hepatol Res 2007; 37: S83-7.
37. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37: S88-94.
38. Lo CM, Fan ST, Liu CL, et al. Ten-year experience with liver transplantation at Queen Mary Hospital: retrospective study. Hong Kong Med J 2002; 8: 240-4.
39. Park JY, Ahn SH, Yoon YJ, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-37.
40. Han KH, Seong J, Kim JK, et al. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
41. Mathurin P, Rixe O, Carbonell N, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 1998; 12: 111-26.
42. Llovet JM, Ricci S, Mazzaferro V, et al. For the SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
43. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
44. Zhu AX, Sahani DV, di Tomaso E, et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): insights from a multidisciplinary phase II study. J Clin Oncol 2008; 26 (abstract 4521).
45. Faivre SJ, Raymond E, Douillard J, et al. Journal of Clinical Oncology 2007. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 3546.
46. Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): a multicenter phase II trial (SAKK 77/06 and SASL 23). J Clin Oncol 2009; 27: 15s (abstract 4591).
47. Hoda D, Catherine C, Strosberg J, et al. Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC). 2008 ASCO Gastrointestinal Cancers Symposium, abstract no. 267.
48. Raoul JL, Finn RS, Kang YK, et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2009; 27: 15s (abstract 4577).
49. Finn RS, Kang Y, Park J, et al. Phase II, open label study of brivanib alaninate in patients (pts) with hepatocellular carcinoma (HCC) who failed prior antiangiogenic therapy. 2009 ASCO Gastrointestinal Cancers Symposium, abstract no. 200.
50. Toh HC, Chen P, Knox JJ, et al. International phase 2 trial of ABT-869 in patients with advanced hepatocellular carcinoma (HCC). Eur J Cancer Suppl 2009; 7: 366. Abstract PD-6517.
51. Hsu C, Yang TS, Huo TL, et al. Evaluation of vandetanib in patients with inoperable hepatocellular carcinoma (HCC): a randomized, double-blind, parallel group, multicentre, phase II study. Joint ECCO 15-34th ESMO Multidisciplinary Congress 2009, abstract no. PD-6518. Available at http://ex2.excerptamedica.com/CIW-09ecco/index.cfm?fuseaction=CIS2002&hoofdnav=Abstracts&content=abs.details&what=AUTHOR&searchtext=hsu&topicselected=&selection=ABSTRACT&qryStartRowDetail=7 (accessed 2 November 2009).
52. Yau CC, Chen PJ, Curtis M, et al. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 15s (abstract 3561).
53. Govindarajan R, Siegel ER, Makhoul I, Williamson SK. Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC). 2009 ASCO Gastrointestinal Cancers Symposium, abstract no. 264.
54. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-50.
55. Kaseb AO, Iwasaki M, Javle M, et al. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol (abstract 4522).
56. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008; 75: 1-12.
57. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rational for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.
58. Llovet JM, Bruix J. Systemic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
59. Yeung YP, Lo CM, Liu CL, et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 1995-2004.
60. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-65.
61. Lee HC. Systemic chemotherapy of hepatocellular carcinoma - Korean experience. Oncology 2008; 75: 114-8.
62. Meza-Junco J, Chu QS, Christensen O, et al. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 2009; 65: 1-4.
63. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 2001; 35: 421-30.
64. Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010; 21: 7-12.